Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple all... Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies. Show more
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Cemacabtagene Ansegedleucel (Cema-Cel): 1L Consolidation in Large B-Cell Lymphoma (LBCL) Pivotal Phase 2 ALPHA3 Trial Initiated in June 2024Patient Screening for Minimal Residual Disease (MRD) and...
Conference Call and Webcast Scheduled for August 7, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc.Β (Nasdaq: ALLO...
Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Institute; Astera Cancer Care, Part of the OneOncology Network; and Norton...
ALPHA3 Trial Has the Potential to Position Cema-cel as Part of First Line (1L) Treatment for LBCL to Improve Cure RatesFirst Prospective Trial to Incorporate the Foresight Diagnosticsβs...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.05 | 1.81818181818 | 2.75 | 3.065 | 2.64 | 2545093 | 2.89235209 | CS |
4 | 0.18 | 6.87022900763 | 2.62 | 3.065 | 2.37 | 1944926 | 2.74554087 | CS |
12 | 0.36 | 14.7540983607 | 2.44 | 3.67 | 2.01 | 2171329 | 2.72765803 | CS |
26 | -1.59 | -36.2186788155 | 4.39 | 4.63 | 2.01 | 2352301 | 2.84404451 | CS |
52 | -1.1 | -28.2051282051 | 3.9 | 5.775 | 2.01 | 2456942 | 3.14737544 | CS |
156 | -21.89 | -88.6593762657 | 24.69 | 27.86 | 2.01 | 2139257 | 6.97138158 | CS |
260 | -29.84 | -91.4215686275 | 32.64 | 55 | 2.01 | 1610929 | 12.06681579 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.